Determination of Three Potential Genotoxic Impurities in Imatinib Mesylate by Gas Chromatography—Mass Spectrometry

References

• Carlin, J., N. Gregory, and J. Simmons. 1998. Stability of isoniazid in isoniazid syrup: Formation of hydrazine. Journal of Pharmaceutical and Biomedical Analysis 17:885–90. doi:10.1016/s0731-7085(98)00002-8
   PubMed Web of Science ®Google Scholar
• Christina, A. E., V. M. Blas Ferrando, F. de Bordes, W. A. Spruit, H. S. Overkleeft, J. D. C. Codée, and G. A. van der Marel. 2012. Multigram-scale synthesis of an orthogonally protected 2-acetamido-4-amino-2,4,6-trideoxy-d-galactose (AAT) building block. Carbohydrate Research 356:282–87. doi:10.1016/j.carres.2012.02.015
   PubMed Web of Science ®Google Scholar
• Easmon, J., G. Pürstinger, K. S. Thies, G. Heinisch, and J. Hofmann. 2006. Synthesis, structure-activity relationships, and antitumor studies of 2-benzoxazolyl hydrazones derived from alpha-(N)-acyl heteroaromatics. Journal of Medicinal Chemistry 49:6343–50. doi:10.1021/jm060232 u
   PubMed Web of Science ®Google Scholar
• Elder, D. P., D. Snodin, and A. Teasdale. 2011. Control and analysis of hydrazine, hydrazides and hydrazones—Genotoxic impurities in active pharmaceutical ingredients (APIs) and drug products. Journal of Pharmaceutical and Biomedical Analysis 54:900–10. doi:10.1016/j.jpba.2010.11.007
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (EMEA). 2010. Guideline on the limits of genotoxic impurities, 28 June, 2006, Together with a supplementary document, Questions and answers on the ‘Guideline on the limits of genotoxic impurities, 23 September 2010.
   Google Scholar
• European Medicines Agency (EMEA). 2008. International Conference on Harmonisation (ICH) Topic S9. Nonclinical evaluation for anticancer pharmaceuticals.
   Google Scholar
• Gyllenhaal, O., L. Gronberg, and J. Vessman. 1990. Determination of hydrazine in hydralazine by capillary gas chromatography with nitrogen-selective detection after benzaldehyde derivatization. Journal of Chromatography A 511:303–15. doi:10.1016/s0021-9673(01)93293-5
   PubMed Web of Science ®Google Scholar
• International Conference on Harmonisation (ICH). 2013. Guideline M7. Assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk.
   Google Scholar
• International Conference on Harmonisation (ICH). 2005. Guideline Q2(R1). Validation of Analytical Procedures.
   Google Scholar
• Jagota, N. K., A. J. Chetram, and J. B. Nair. 1998. Determination of trace levels of hydrazine in the penultimate intermediate of a novel anti-infective agent. Journal of Pharmaceutical and Biomedical Analysis 16:1083–87. doi:10.1016/s0731-7085(97)00053-8
   PubMed Web of Science ®Google Scholar
• Kean, T., J. H. Miller, G. G. Skellern, and D. Snodin. 2006. Acceptance criteria for levels of hydrazine in substances for pharmaceutical use and analytical methods for its determination. Pharmeuropa Scientific Notes 2:23–33.
   Google Scholar
• Kil, K. E., Y. S. Ding, K. S. Lin, D. Alexoff, S. W. Kim, C. Shea, Y. Xu, L. Muench, and J. S. Flower. 2007. Synthesis and positron emission tomography studies of carbon-11-labeled imatinib (Gleevec). Nuclear Medicine and Biology 34:153–63. doi:10.1016/j.nucmedbio.2006.11.004
   PubMed Web of Science ®Google Scholar
• Kirtley, A., S. Strickfuss, and P. M. Yehl. 2006. Determination of residual hydrazine in a high dose drug. Pharmeuropa Scientific Notes 2:23–33.
   Google Scholar
• Li, Z., J. Han, Y. Jiang, P. Browne, R. J. Knox, and L. Hu. 2003. Nitrobenzocyclophosphamides as potential prodrugs for bioreductive activation: Synthesis, stability, enzymatic reduction, and antiproliferative activity in cell culture. Bioorganic & Medicinal Chemistry 11:4171–78. doi:10.1016/s0968-0896(03)00459-0
   PubMed Web of Science ®Google Scholar
• Liew, D., K. L. Linge, C. A. Joll, A. Heitz, and J. W. A. Charrois. 2012. Determination of halonitromethanes and haloacetamides: An evaluation of sample preservation and analyte stability in drinking water. Journal of Chromatography A 1241:117–22. doi:10.1016/j.chroma.2012.04.037
   PubMed Web of Science ®Google Scholar
• Liu, M., J. Ostrovic, E. X. Chen, and N. Cauchon. 2009. Hydrophilic interaction liquid chromatography with alcohol as a weak eluent. Journal of Chromatography A 1216:2362–70. doi:10.1016/j.chroma.2009.01.012
   PubMed Web of Science ®Google Scholar
• Meloncelli, P. J., L. J. West, and T. L. Lowary. 2011. Synthesis and NMR studies on the ABO histo-blood group antigens: Synthesis of type III and IV structures and NMR characterization of type I–VI antigens. Carbohydrate Research 346:1406–26. doi:10.1016/j.carres.2011.03.008
   PubMed Web of Science ®Google Scholar
• Ng, J., P. Wang, J. Baez, C. Liu, D. Anderson, J. Lawson, B. Erb, J. Wieczorek, G. Mucciariello, F. Vanzanella, S. Kunda, L. Letendre, M. Pozzo, Y.-L. Sing, and E. Yonan. 2002. Epoxidation of cyclopenta(a)phenanthrene derivatives. US 20020016455 A1.
   Google Scholar
• Plum, A., W. Engewald, and A. Rehorek. 2003. Rapid qualitative pyrolysis GC-MS analysis of carcinogenic aromatic amines from dyed textiles. Chromatographia 57:243–48. doi:10.1007/bf02492110
   Web of Science ®Google Scholar
• Raman, N. V. V. S. S., A. V. S. S. Prasad, and K. R. Reddy. 2011. Strategies for the identification, control and determination of genotoxic impurities in drug substances: A pharmaceutical industry perspective. Journal of Pharmaceutical and Biomedical Analysis 55:662–67. doi:10.1016/j.jpba.2010.11.039
   PubMed Web of Science ®Google Scholar
• Srinivasu, M. K., D. S. Rao, and O. Reddy. 2002. Determination of celecoxib, a COX-2 inhibitor, in pharmaceutical dosage forms by MEKC. Journal of Pharmaceutical and Biomedical Analysis 28:493–500. doi:10.1016/s0731-7085(01)00670-7
   PubMed Web of Science ®Google Scholar
• Sun, M., L. Bai, and D. Q. Lui. 2008. A generic approach for the determination of trace hydrazine in drug substances using in situ derivatization-headspace-GC–MS. Journal of Pharmaceutical and Biomedical Analysis 49:529–33. doi:10.1016/j.jpba.2008.11.009
   PubMed Web of Science ®Google Scholar
• Szczepek, W., W. Łuniewski, L. Kaczmarek, B. Zagrodzki, D. Samson-Łazińska, W. Szelejewski, and M. Skarżyński. 2010. Process for preparation of imatinib base US 7,674,901.
   Google Scholar
• Teasdle, A., D. Elder, S. J. Chang, S. Wang, R. Thompson, N. Benz, and I. H. Snaches Flores. 2010. Risk assessment of genotoxic impurities in new chemical entities: Strategies to demonstrate control. Organic Process Research & Development 82:2865–72. doi:10.1021/op300268 u
   Google Scholar
• Wang, W., L. Bavda, N. Benz, G. Brill, D. Chou, W. Pritts, M. Rog, A. Schellinger, Q. Zhang, S. Zhang, Y. Zhou, and J. Zheng. 2008. Analytical methodologies for detection and quantitation of genotoxic impurities. In Presentation at Informa Genotoxic Impurities Meeting, Philadelphia, 02–04th December.
   Google Scholar
• Wu, L., W. Liu, J. Cao, Q. Li, Y. Huang, and S. Min. 2013. Analysis of the aroma components in tobacco using combined GC-MS and AMDIS. Analytical Methods 5:1259–63. doi:10.1039/c2ay26102b
   Web of Science ®Google Scholar